Cannara Biotech (CNSX:LOVE – Get Free Report) had its price target lifted by research analysts at TD from $3.25 to $4.00 in a report issued on Thursday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock.
Separately, Haywood Securities set a $3.00 price target on shares of Cannara Biotech and gave the stock a “buy” rating in a report on Monday, April 6th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $3.42.
Get Our Latest Stock Report on Cannara Biotech
Cannara Biotech Stock Performance
Cannara Biotech Company Profile
Cannara Biotech Inc is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec’s low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands.
Further Reading
- Five stocks we like better than Cannara Biotech
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Cannara Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannara Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
